Educational Tools

Biosimilars

• Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.
• Biosimilars: implications for rheumatoid arthritis therapy.
• The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
• Clinical trials of biosimilars should become more similar.
• Biosimilars: More Treatment Options Are on the Way
• FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US

Giant Cell Arteritis

• Giant Cell Arteritis – Fast Facts for Patients
• Giant Cell Arteritis – Vasculitis Foundation
• ACR Classification of Giant Cell Arteritis
• Recognition and Management of Giant Cell Arteritis
• GIACTA Trial of Tocilizumab in Giant Cell Arteritis
• Giant Cell Arteritis

Gout

• Treat to target in gout

Immune-mediated adverse reactions

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Clinical Practice Guideline
• The management of immune-related adverse events associated with immune checkpoint blockade
• The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy
• Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities
• Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
• Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
• Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

Spondyloarthritis

• What Is Axial Spondyloarthritis (AxSpA)?
• Recommendations for the Treatment of Ankylosing Spondylitis

Juvenile Idiopathic Arthritis (JIA)

• ACR Update of Recommendations to the Treatment of JIA
• What is JIA? - Patient Handout

Rheumatoid Arthritis (RA)

• RA and Vaccinations
• JAK Inhibitors for Rheumatoid Arthritis
• IL-6 Inhibitors for Rheumatoid Arthritis
• TNF-alpha inhibitors for Rheumatoid Arthritis
• RA Treat-to-Target Recommendations
• The Purple Book for Biosimilars
• 2015 ACR Guideline for the Treatment of RA
• RA Overview (for Patients)
• RA Treatment (for Patients)
• Biologic-free Remission in Established RA
• EULAR Recommendations Update: Management of RA
• RA Drug Guide: Analgesics, Steroids, Biologics, DMARDs, NSAIDs - For Patients